The Irish Medicines Board - www.imb.ie

Home
About Us
Consultation
Events
Glossary
Legislation
Links
News
Publications
Recruitment
Register

Safety & Quality
Human Medicines
Veterinary
Medical Devices
Blood, Tissues, Organs
Cosmetics
Patients & Public

Your Selection

[x] Year: 2008
[x] Remove All Filters

By Product

Blood, Tissues & Cells (5)
Cosmetics (3)
Drug-Device Combination Products (5)
Herbal & Homeopathic Medicines (5)
Human medicines (47)
Medical devices (4)
Veterinary (6)

By Audience / Stakeholder Group

All Stakeholders (4)
Healthcare professionals (42)
Industry (22)

By Document Type

Corporate & Policy Documents (3)
Direct Healthcare Professional Communication (30)
Forms & Templates (8)
Guidance (11)
Newsletters (9)
Safety Updates & Reports (2)

By Service

Clinical Trials (2)
Exempt Products (1)
Licensing – Medicines (10)
Product Classification (1)
Reporting Safety & Quality issues (3)

Raptiva (efalizumab)-Important Safety Information from Merck Serono on the association of efalizumab with PML

04 November 2008

Tags: Human medicines Healthcare professionals Direct Healthcare Professional Communication 2008

Please find herewith an important safety communication from Merck Serono on the association of efalizumab (Raptiva) with progressive multifocal leukoencephalopathy (PML)

Raptiva (efalizumab)-Important Safety Information

« View Publications List

Provide Feedback

RSS Feeds

IMB Publications RSS Feed

Date Printed: 21 May 2013

Address: Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Ireland.
Tel: 353-1-676 4971